SCHEMBL4359022

SCHEMBL4359022

Oc1ccc2c(c1)C(O)CC(c1cccc(Oc3ccccn3)c1)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 6/20 0.41
MGLL Q99685 1/20 0.38
ESR1 P03372 2/20 0.35
ESR2 Q92731 2/20 0.35
AR P10275 2/20 0.34
FFAR4 Q5NUL3 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TLR4 O00206 1/20 0.34
TLR2 O60603 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
IP6K1 Q92551 1/20 0.33
IP6K3 Q96PC2 1/20 0.33
IP6K2 Q9UHH9 1/20 0.33
GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361883 0.85 CYP19A1 (0.35) CYP19A1MGLLESR1ESR2
SCHEMBL4362360 0.81 CA2 (0.46) CYP19A1ESR1ESR2ALDH1A1GAA
SCHEMBL4360085 0.80 ESR1 (0.53) ESR1ESR2
SCHEMBL4359940 0.80 CYP19A1 (0.49) CYP19A1ARALDH1A1CYP3A4
SCHEMBL4362361 0.80 AR (0.61) CYP19A1ESR2ARCYP3A4
SCHEMBL4367671 0.78 ESR1 (0.51) CYP19A1ESR1ESR2ARCYP3A4
SCHEMBL6205761 0.78 KDM4E (0.46) CYP19A1ALDH1A1HSD17B10
SCHEMBL4365834 0.77 AR (0.54) CYP19A1ESR1ESR2ARALDH1A1
Hydrochloric Acid SCHEMBL4361996 0.77 KDM4E (0.45) CYP19A1ALDH1A1HSD17B10
SCHEMBL4366178 0.74 ESR1 (0.41) CYP19A1ESR1ESR2ARCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482340-B2 Pyridine derivatives useful for inhibiting sodium/calcium exchange system ORION CORPORATION (FI) 2009-01-27 US disclosed
US-20060241147-A1 Pyridine derivatives useful for inhibiting sodium/calcium exchange system ORION CORPORATION (FI) 2006-10-26 US disclosed
EP-1583759-A1 PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM ORION CORPORATION (FI) 2005-10-12 EP disclosed
WO-2004063191-A1 PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM ORION CORPORATION (FI) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241147-A1 Pyridine derivatives useful for inhibiting sodium/calcium exchange system SLC8B1, CACNA1A, MCU CYP19A1 2119/4885MGLL 3581/4885ESR1 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.